Select Page

Remopain pre-filled syringes

Dexa Medica

Product packaging may vary from one country to another.

Ingredients in every ml

Ketorolac 30 mg

Each package contains

5 syringes of 1 ml

Other details

Dosage form:Syringe; pre-filled
Flavour None

W.H.O. classification

ATC Level 1 M - Musculo-skeletal system
ATC Level 2 M01 - Antiinflammatory and Antirheumatic Products
ATC Level 3 M01A - Antiinflammatory and Antirheumatic Products; Non-Steroids

Warnings

Pregnancy

NOT RECOMMENDEDThis item is not safe for use during pregnancy.

Lactation

NOT RECOMMENDEDThis item is not safe for use during lactation.

Alcohol

CAUTIONThis item may not be safe for use with alcohol. Use with caution and after consultation with your doctor.

Machinery

CONSULT YOUR DOCTORSafety of this item for use while operating heavy machinery has not been established. Please consult your doctor.

Available in

Indonesia

Dosage information

16 TO 65 YEARS OLD
— Single dose IM: 1x60 mg
— Single dose IV: 1x30 mg
— Repeated IM or IV: 30 mg every 6 hours, maximum 120 mg daily

Long-term treatment of ketorolac IV and IM should not exceed 5 days. Hypovolemia should be corrected prior to the administration of ketorolac trometamol. The IV bolus must be given over no less than 15 seconds. The IM administration should be given deeply and slowly into the muscle. The analgesic effect begins in 30 minutes with maximum effect occurring in 1-2 hours after dosing IV or IM. The duration of analgesic effect is usually 4-6 hours. For breakthrough pain, do not increase the dose or the frequency of ketorolac trometamol. Consideration should be given to supplementing these regiments with low doses of opioids unless otherwise contraindicated.

65 YEARS OLD AND ABOVE
— Single dose IM: 1x30 mg
— Single dose IV: 1x15 mg
— Repeated IM or IV: 15 mg every 6 hours, maximum 60 mg daily

Long-term treatment of ketorolac IV and IM should not exceed 5 days. Hypovolemia should be corrected prior to the administration of ketorolac trometamol. The IV bolus must be given over no less than 15 seconds. The IM administration should be given deeply and slowly into the muscle. The analgesic effect begins in 30 minutes with maximum effect occurring in 1-2 hours after dosing IV or IM. The duration of analgesic effect is usually 4-6 hours. For breakthrough pain, do not increase the dose or the frequency of ketorolac trometamol. Consideration should be given to supplementing these regiments with low doses of opioids unless otherwise contraindicated.

0 TO 16 YEARS OLD
Ketorolac trometamol is not recommended .

Long-term treatment of ketorolac IV and IM should not exceed 5 days. Hypovolemia should be corrected prior to the administration of ketorolac trometamol. The IV bolus must be given over no less than 15 seconds. The IM administration should be given deeply and slowly into the muscle. The analgesic effect begins in 30 minutes with maximum effect occurring in 1-2 hours after dosing IV or IM. The duration of analgesic effect is usually 4-6 hours. For breakthrough pain, do not increase the dose or the frequency of ketorolac trometamol. Consideration should be given to supplementing these regiments with low doses of opioids unless otherwise contraindicated.

PATIENTS WITH HEPATIC IMPAIRMENT
Ketorolac should be used with caution in patients with impaired hepatic function or a history of liver disease. Ketorolac therapy increases hepatic enzymes and in hepatic disease patients, severe hepatic risk reaction may occur. Administration of ketorolac should be discontinued if abnormality of hepatic function test occurs after ketorolac administration.

Indication

Ketorolac is indicated for the short-term (≤5 days) management of severe acute pain that requires analgesia at the opioid level.